Xilio Therapeutics (XLO) EBITDA Margin (2024 - 2026)

Xilio Therapeutics has disclosed EBITDA Margin across 3 years of filings, most recently posting 75.34% for Q1 2026.

• EBITDA Margin for Q1 2026 came in at 75.34%, up 37739.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 58.52% (up 52702.0% YoY), and the FY2025 annual result was 80.05%, up 83800.0% from the prior year.
• EBITDA Margin came in at 75.34% for Q1 2026 at Xilio Therapeutics, down from 75.7% in the prior quarter.
• In the past five years, EBITDA Margin ranged from a high of 75.7% in Q4 2025 to a low of 759.45% in Q4 2024.
• The 3-year median for EBITDA Margin is 324.36% (2025), against an average of 337.95%.
• Across the five-year window, EBITDA Margin surged 83515 bps in 2025 and soared 37739 bps in 2026, its largest moves.
• Xilio Therapeutics' EBITDA Margin stood at 759.45% in 2024, then soared by 110 bps to 75.7% in 2025, then slumped by 200 bps to 75.34% in 2026.
• The last three EBITDA Margin figures came in at 75.34% (Q1 2026), 75.7% (Q4 2025), and 85.42% (Q3 2025), per Business Quant data.